What kind of people are "engines"? Studies show that they are more likely to be psychopaths, sadists, and narcissists.

Published Date: 17 Feb 2023

Online dating has revolutionized dating by creating more opportunities to meet partners than ever before.

Read Full News

Latest News

Q3 2026 Recap: Psychiatry News and Updates

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know Andrew Leuchter, MD, Scott A. Wilke, MD, PhD, Linda Carpenter, MD

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD John Sonnenberg, PhD

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Q2 2026 Recap: Psychiatry News & Updates Chelsie Derman

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

Todays Updates

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Todays Updates

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Latest News

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

News All Time

FDA Approves Centanafadine for ADHD in Adults, Children Aged ≥ 6 Years Chelsie Derman

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.

Ketamine, Psychedelics Share Neuroimmune Signature in TRD Chelsie Derman

A biomarker study links immune signaling (IL-7/IL-15) and brain gamma-wave activity to ketamine response in TRD.

Metabolic Traits Differentiate AERS+, AERS− MDD Subtypes, With Arvid Harder Arvid Harder

New genome-wide data show AERS+ and AERS− subtypes of major depressive disorder diverge in heritability and metabolic genetic correlations.

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial Chelsie Derman

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

AERS Subtypes Show Distinct Genetic Architecture in MDD Arvid Harder

A genome-wide study of > 460,000 individuals identify 27 loci separating AERS+ and AERS− subtypes of major depressive disorder by metabolic profile.

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD Chelsie Derman

Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD Jonathan Downar, MD, PhD

Downar says shorter sessions, accelerated schedules, and expanding neuroimaging maps have made TMS effective for more patients in far fewer visits.

Lower TMS Intensity Correlates With Greater Depression Improvement Chelsie Derman

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD Chelsie Derman

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Do More TMS Pulses Track with Better Depression Outcomes? Jonathan Downar, MD, PhD

A new meta-analysis found total pulse count predicted outcomes in a roughly linear pattern across sham-controlled trials of accelerated rTMS.

Q&A: Accelerated TMS Speeds Suicidal Ideation Relief, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

SWIFT accelerated Deep TMS resolved suicidal ideation faster than standard dosing, Owen Muir, MD, says.

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Walmart Pasta Recall; 'Ketamine Bladder' in Kids; Panettiere's Cause of Death

Health news and commentary gathered by MedPage Today staff

Safety Concerns Halt Depression Trials; Gen Z and Alcohol; Prescribing Benzos

— News and commentary from the psychiatry world

Recommended News For You

Headlines About Doc Who 'Catches' Patient's Cancer Are Popping Up Again

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

Loneliness and social isolation linked to heightened risk of death in those with cancer

What Do Patients Want Doctors to Know About Breast Cancer Recurrence?

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

Medicaid expansion tied to smaller declines in early-stage cancer detection

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Recommended Articles For You

Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes 

Progressive Updates in Oncology for Healthcare Excellence 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In schizophrenia, sexual dysfunction is frequent.

2.

Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting

3.

Why breast cancer survivors don't take their medicine, and what can be done about it.

4.

Eliminating the SRC-3 gene in immune cells causes an efficient, long-lasting anti-cancer response.

5.

High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment

1.

Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies

2.

Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer

3.

AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology

4.

Teaching Hematology Through Morphology-Based Learning

5.

Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

2.

How Iron Deficiency Can Affect Energy and Concentration

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

Blood Clotting Disorders Explained

5.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot